280 related articles for article (PubMed ID: 30607682)
1. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer.
Wang X; He Y; Wang T; Xie Y; Li J; Ouyang T; Fan Z
Support Care Cancer; 2019 Aug; 27(8):3019-3025. PubMed ID: 30607682
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of adjuvant dose-dense docetaxel/epirubicin/cyclophosphamide (TEC) in stage II and III breast cancer.
Burdette-Radoux S; Wood ME; Olin JJ; Laughlin RS; Crocker AM; Ashikaga T; Muss HB
Breast J; 2007; 13(3):274-80. PubMed ID: 17461902
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.
Morita S; Kikumori T; Tsunoda N; Inaishi T; Adachi Y; Ota A; Shibata M; Matsuoka A; Nakanishi K; Takeuchi D; Mizutani T; Shimokata T; Hayashi H; Maeda O; Ando Y
Int J Clin Oncol; 2018 Feb; 23(1):195-200. PubMed ID: 28791509
[TBL] [Abstract][Full Text] [Related]
4. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
Kourlaba G; Dimopoulos MA; Pectasides D; Skarlos DV; Gogas H; Pentheroudakis G; Koutras A; Fountzilas G; Maniadakis N
Support Care Cancer; 2015 Jul; 23(7):2045-51. PubMed ID: 25524005
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
7. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Kosaka Y; Rai Y; Masuda N; Takano T; Saeki T; Nakamura S; Shimazaki R; Ito Y; Tokuda Y; Tamura K
Support Care Cancer; 2015 Apr; 23(4):1137-43. PubMed ID: 25576433
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.
Burstein HJ; Parker LM; Keshaviah A; Doherty J; Partridge AH; Schapira L; Ryan PD; Younger J; Harris LN; Moy B; Come SE; Schumer ST; Bunnell CA; Haldoupis M; Gelman R; Winer EP
J Clin Oncol; 2005 Nov; 23(33):8340-7. PubMed ID: 16293865
[TBL] [Abstract][Full Text] [Related]
9. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
10. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Jones RL; Walsh G; Ashley S; Chua S; Agarwal R; O'Brien M; Johnston S; Smith IE
Br J Cancer; 2009 Jan; 100(2):305-10. PubMed ID: 19165198
[TBL] [Abstract][Full Text] [Related]
11. Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Mattioli R; Gridelli C; Castellanos J; Duque A; Falcone A; Mansutti M; Bacon P; Lawrinson S; Skacel T; Casas A
Clin Transl Oncol; 2009 Dec; 11(12):842-8. PubMed ID: 20045791
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Natoli C; Cianchetti E; Tinari N; Angelucci D; Grassadonia A; Zilli M; Ficorella C; Ricevuto E; Grossi S; De Tursi M; Carella C; Rispoli AI; Iacobelli S
Ann Oncol; 2007 Jun; 18(6):1015-20. PubMed ID: 17369601
[TBL] [Abstract][Full Text] [Related]
13. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Zhang W; Jiang Z; Wang L; Li C; Xia J
Med Oncol; 2015 May; 32(5):147. PubMed ID: 25820754
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.
Mizuno Y; Fuchikami H; Takeda N; Iwai M; Sato K
Jpn J Clin Oncol; 2017 Jan; 47(1):12-17. PubMed ID: 28122890
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
Kahan Z; Grecea D; Smakal M; Tjulandin S; Bondarenko I; Perjesi L; Illes A; Horvat-Karajz K; Aradi I
BMC Cancer; 2019 Feb; 19(1):122. PubMed ID: 30727980
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial.
Blackwell K; Donskih R; Jones CM; Nixon A; Vidal MJ; Nakov R; Singh P; Schaffar G; Gascón P; Harbeck N
Oncologist; 2016 Jul; 21(7):789-94. PubMed ID: 27091420
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
Green MD; Koelbl H; Baselga J; Galid A; Guillem V; Gascon P; Siena S; Lalisang RI; Samonigg H; Clemens MR; Zani V; Liang BC; Renwick J; Piccart MJ;
Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
[TBL] [Abstract][Full Text] [Related]
18. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients.
Möbus V; von Minckwitz G; Jackisch C; Lück HJ; Schneeweiss A; Tesch H; Elling D; Harbeck N; Conrad B; Fehm T; Huober J; Müller V; Bauerfeind I; du Bois A; Loibl S; Nekljudova V; Untch M; Thomssen C;
Ann Oncol; 2017 Aug; 28(8):1803-1810. PubMed ID: 28459941
[TBL] [Abstract][Full Text] [Related]
19. A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
Eckstrom J; Bartels T; Abraham I; Patel H; Elquza E; Scott AJ; Malangone S; Hollings J; McBride A
Support Care Cancer; 2019 Mar; 27(3):873-878. PubMed ID: 30090991
[TBL] [Abstract][Full Text] [Related]
20. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
